Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis.
We undertook a prospective, controlled study to evaluate the effect of trimethoprim-sulfamethoxazole in children with proven Escherichia coli O157:H7 enteritis on the duration fo symptoms, on fecal excretion of pathogen, and on the risk of progression to hemolytic-uremic syndrome. There was no statistically significant effect of treatment on progression of symptoms, fecal pathogen excretion, or the incidence of HUS (2/22 vs 4/25; p = 0.67). Our results suggest that a multicentric trial using rapid diagnostic methods to permit early randomization should be carried out.
Proulx
F
F
Department of Pediatrics, Sainte-Justine Hospital, Université de Montréal, Québec, Canada.
Turgeon
J P
JP
Delage
G
G
Lafleur
L
L
Chicoine
L
L
D002648:Child; D002675:Child, Preschool; D004751:Enteritis / Q000188:drug therapy* / Q000382:microbiology; D004926:Escherichia coli / Q000145:classification / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy*; D005243:Feces / Q000382:microbiology; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology; D006801:Humans; D007223:Infant; D008297:Male; D011446:Prospective Studies; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
D015662:Trimethoprim, Sulfamethoxazole Drug Combination